Avalo Therapeutics appoints Mittie Doyle, M.D., as CMO; grants 234,000-share option

Avalo Therapeutics, Inc.

Dr. Doyle, former CMO at Aro Biotherapeutics, brings over 20 years of pharma/biotech experience.
She will lead Phase 2 LOTUS Trial for AVTX-009 in hidradenitis suppurativa.
Base salary of $500,000, target bonus of 40%, and inducement stock option for 234,000 shares vesting over 4 years.
Severance includes nine months' salary (12 months post-change-in-control), full option vesting, and COBRA.
Appointment effective July 15, 2024; employment agreement filed as Exhibit 10.1.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Mittie Doyle

Chief Medical Officer

AVTX · Avalo Therapeutics, Inc.

Effective: 2024-07-15
Filed: July 16, 2024, 7:59 PM ET

On July 16, 2024, Avalo Therapeutics, Inc. (the “Company”) announced the appointment of Mittie Doyle, M.D., FACR, as Chief Medical Officer, effective July 15, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Mittie Doyle was appointed as Chief Medical Officer at Avalo Therapeutics, Inc..

Action: appointed
Role: Chief Medical Officer

Exact text from the filing

On July 16, 2024, Avalo Therapeutics, Inc. (the “Company”) announced the appointment of Mittie Doyle, M.D., FACR, as Chief Medical Officer, effective July 15, 2024.

View on SEC.gov

Avalo Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-24-031923

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.